AMRZ Stock Analysis: Amrize | NYSE
Building Materials | NYSE, USA | Market Cap: 20.532m USD | 12M Return: -18.3% | CH1430134226 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 169M
Qual. Beats: 0
Rev. Trend: 94.4%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amrize AG is a Swiss-domiciled building solutions provider serving infrastructure, commercial, and residential construction markets across North America. The company operates through two segments: Building Materials, which supplies cement, aggregates, ready-mix concrete, asphalt, and other construction materials; and Building Envelope, which offers roofing and wall systems such as single-ply membranes, insulation, shingles, sheathing, waterproofing, protective coatings, adhesives, tapes, and sealants. Amrize was spun out as the North American business of global cement major Holcim and completed its NYSE listing (AMRZ) in June 2025.
The companys business model spans both upstream construction inputs (cement and aggregates) and downstream building components (roofing and wall systems), giving it a vertically integrated position across the North American construction value chain. Its GICS classification within the Construction Materials sub-industry places it among producers of commodity-heavy inputs whose demand tends to track infrastructure spending, housing starts, and non-residential construction cycles.
- US infrastructure spending boosts cement and aggregates demand
- Housing starts decline pressures North American construction volumes
- Cement price increases offset energy and labor cost inflation
| Net Income: 1.21b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.54 > 1.0 |
| NWC/Revenue: 3.53% < 20% (prev 10.20%; Δ -6.67% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.18b > Net Income 1.21b |
| Net Debt (7.05b) to EBITDA (2.84b): 2.48 < 3 |
| Current Ratio: 1.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (553.6m) vs 12m ago 0.09% < -2% |
| Gross Margin: 25.03% > 18% (prev 25.93%; Δ -0.90% > 0.5%) |
| Asset Turnover: 50.37% > 50% (prev 48.76%; Δ 1.61% > 0%) |
| Interest Coverage Ratio: 5.68 > 6 (EBIT TTM 1.89b / Interest Expense TTM 333.0m) |
| A: 0.02 (Total Current Assets 4.58b - Total Current Liabilities 4.15b) / Total Assets 24.6b |
| B: 0.04 (Retained Earnings 997.0m / Total Assets 24.6b) |
| C: 0.08 (EBIT TTM 1.89b / Avg Total Assets 24.2b) |
| D: 1.09 (Book Value of Equity 12.9b / Total Liabilities 11.7b) |
| Altman-Z'' = 1.92 = BBB |
| DSRI: 1.03 (Receivables 2.06b/1.89b, Revenue 12.2b/11.6b) |
| GMI: 1.04 (GM 25.93% / 25.03%) |
| AQI: 0.96 (AQ_t 0.45 / AQ_t-1 0.47) |
| SGI: 1.05 (Revenue 12.2b / 11.6b) |
| TATA: -0.04 (NI 1.21b - CFO 2.18b) / TA 24.6b) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 38.22 with a total of 3,576,184 shares traded. Over the past week, the price has changed by +1.81%, over one month by -13.63%, over three months by -31.44% and over the past year by -18.30%.
Current recommended Stop Loss: 36.50 (which is 4.5% or 1.4 ATR below the current price).
Amrize has no consensus analysts rating.
P/E Trailing = 16.8341
P/E Forward = 12.6904
P/S = 1.6853
P/B = 1.5958
P/EG = 0.9778
Revenue TTM = 12.2b USD
EBIT TTM = 1.89b USD
EBITDA TTM = 2.84b USD
Long Term Debt = 4.24b USD (from longTermDebt, last quarter)
Short Term Debt = 1.90b USD (from shortTermDebt, last quarter)
Debt = 7.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.15b
Net Debt = 7.05b USD (calculated: Debt 7.78b - CCE 729.0m)
Enterprise Value = 27.6b USD (20.5b + Debt 7.78b - CCE 729.0m)
Interest Coverage Ratio = 5.68 (Ebit TTM 1.89b / Interest Expense TTM 333.0m)
EV/FCF = 20.88x (Enterprise Value 27.6b / FCF TTM 1.32b)
FCF Yield = 4.79% (FCF TTM 1.32b / Enterprise Value 27.6b)
FCF Margin = 10.84% (FCF TTM 1.32b / Revenue TTM 12.2b)
Net Margin = 9.89% (Net Income TTM 1.21b / Revenue TTM 12.2b)
Gross Margin = 25.03% ((Revenue TTM 12.2b - Cost of Revenue TTM 9.14b) / Revenue TTM)
Gross Margin QoQ = 28.42% (prev 9.69%)
Tobins Q-Ratio = 1.12 (Enterprise Value 27.6b / Total Assets 24.6b)
Interest Expense / Debt = 4.28% (Interest Expense 333.0m / Debt 7.78b)
Taxrate = 23.53% (369.0m / 1.57b)
NOPAT = 1.45b (EBIT 1.89b * (1 - 23.53%))
Current Ratio = 1.10 (Total Current Assets 4.58b / Total Current Liabilities 4.15b)
Debt / Equity = 0.61 (Debt 7.78b / totalStockholderEquity, last quarter 12.9b)
Debt / EBITDA = 2.48 (Net Debt 7.05b / EBITDA 2.84b)
Debt / FCF = 5.34 (Net Debt 7.05b / FCF TTM 1.32b)
Total Stockholder Equity = 13.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.98% (Net Income 1.21b / Total Assets 24.6b)
RoE = 9.25% (Net Income TTM 1.21b / Total Stockholder Equity 13.0b)
RoCE = 10.95% (EBIT 1.89b / Capital Employed (Equity 13.0b + L.T.Debt 4.24b))
RoIC = 6.65% (NOPAT 1.45b / Invested Capital 21.7b)
WACC = 8.45% (E(20.5b)/V(28.3b) * Re(10.41%) + D(7.78b)/V(28.3b) * Rd(4.28%) * (1-Tc(0.24)))
Discount Rate = 10.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 66.04 | Cagr: 0.07%
[DCF] Terminal Value 77.65% ; FCFF base≈1.25b ; Y1≈1.44b ; Y5≈2.11b
[DCF] Fair Price = 44.20 (EV 31.2b - Net Debt 7.05b = Equity 24.2b / Shares 546.9m; r=8.45% [WACC]; 5y FCF grow 14.97% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.24 | # QB: 0
Revenue Correlation: 94.38 | Revenue CAGR: 0.59% | SUE: 1.19 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.06 | Chg30d=+0.84% | Revisions=-57% | Analysts=8
EPS current Year (2026-12-31): EPS=2.46 | Chg30d=-1.11% | Revisions=-80% | GrowthEPS=+15.1% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=2.81 | Chg30d=-4.43% | Revisions=-80% | GrowthEPS=+14.0% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: -90% (up=0, down=28)